VIENNA, Austria, Dec. 20, 2016 /CNW/ -
UNIVERSKIN - is a a unique, science-based and physician dispensed bespoke skincare, bridging skincare and functional dermatology. UNIVERSKIN personalized skincare is successfully used by dermatologists, plastic surgeons and aesthetic practitioners in 23 countries worldwide.
With the aim of further expanding its business activities in the area of dermatological treatments, Austria´s Croma-Pharma GmbH signed a comprehensive licensing and distribution agreement with UNIVERSKIN SAS of France. According to many industry experts, UNIVERSKIN is the most innovative, personalized skincare concept available on the market today. UNIVERSKIN is already highly successfully used by more than 500 dermatologists in France and by dermatologists in 23 countries worldwide.
(Photo: http://mma.prnewswire.com/media/450867/Photo_1_Arampatzis_Prinz.jpg )
(Photo: http://mma.prnewswire.com/media/450882/universkin_primum.jpg )
(Photo: http://mma.prnewswire.com/media/450880/Universkin_1.jpg )
(Photo: http://mma.prnewswire.com/media/450881/Universkin_3.jpg )
The cooperation was concluded for at least 8 years. The exclusive licensing and distribution rights for all UNIVERSKIN products refer to European countries, namely Germany, Austria, France, Poland, Spain, Portugal, the Netherlands and overseas territories such as Australia, Canada and Brazil. For the licenses and distribution rights Croma-Pharma paid an undisclosed amount in a multimillion Euro range. The Agreement shall enter into force on January 1st 2017.
Under its premium brand Princess®, which is exclusively available through dermatologists and pharmacies, Croma-Pharma offers a comprehensive range of products in the field of non-invasive and minimally-invasive aesthetic medicine. The portfolio includes products based on Hyaluronic Acid like intradermal fillers, lifting threads, face masks, serums and the True Hyaluron series. Currently, extensive studies are being conducted in Europe and the USA for the approval of Croma´s new Botulinum Neurotoxin product, which is expected to be approved in 2019. For doctors, Croma offers all relevant dermatological treatments from one single source in the acclaimed quality "Made in Austria" ("one-stop-shop"). The aesthetic portfolio of the Princess® product line is developed and manufactured by Croma-Pharma GmbH at the company´s headquarters in Leobendorf near Vienna, Austria.
The expert combination of Hyaluronic Acid fillers, lifting threads, Botulinum Neurotoxins and state-of-the-art skincare products provide bespoke and lasting results in the minimally-invasive medical anti-aging approach.
Dr. Charalampos Arampatzis, CEO and co-owner of UNIVERSKIN SAS: "Thanks to this promising collaboration with Croma-Pharma, we are enhancing our sales structure in important markets and significantly improve UNIVERSKINs commercial activity through the recognized expertise of the innovation-driven family-owned company Croma-Pharma."
Mag. Pharm. Andreas Prinz, CEO and co-owner of Croma-Pharma GmbH: "With UNIVERSKIN, we are able to implement the most innovative concept in the field of personalized skincare and a unique medical education system into our portfolio. Doing so, Croma-Pharma underlines its leading position as an innovator in the field of non-invasive and minimally invasive aesthetic medicine."
About UNIVERSKIN SAS:
UNIVERSKIN is a pioneer private owned dermatology company, established in 2006 and based in Sophia Antipolis, France. The founding and management team of UNIVERSKIN is comprised of dermatologists, plastic surgeons, pharmacists, biologists, chemists and anatomo-pathologists.
UNIVERSKIN invests massively in research and development to revolutionize skincare and empower doctors to think skin rather than product: back to simplicity for the doctor, more efficacy and a better tolerance for the user. UNIVERSKIN brings a medical logic in skincare: skin medical analysis conducted by trained physicians, choice of active ingredients, concentration, application duration and then monitoring. For the first time, the doctor can design a minimalist, clinically evidenced skincare delivering real results with only one product.
To build each patients formula, a skin medical analysis is conducted by trained physicians, enabling the selection of the relevant active ingredients out of 19 active ingredients available, developed and made in France after 8 years of research. The doctor will choose the actives and concentration, patients will choose the texture. Up to 1159 potential formulas are possible, in 57 different concentrations. In a preparation time of less than two minutes - the skincare formula will be mixed under the doctor´s control, in front of the patient. It will be fine-tuned over time to match patients lifestyle, age, skin condition, seasonal and environmental aggressions.
About Croma-Pharma GmbH:
Founded in 1976, Croma-Pharma is a globally active, family-owned pharmaceutical company based in Leobendorf, Austria. Croma-Pharma is one of the world's most innovative companies in the growth market of minimally-invasive aesthetic medicine (MIAM).
Under its premium brand Princess® Croma offers facial masks, serums, intradermal-fillers, and lifting threads. These high-quality products are distributed exclusively by doctors and pharmacies. With the production of 6 million pre-filled syringes annually and more than 150 million syringes since its inception, Croma-Pharma is a leading producer of Hyaluronic Acid based products. The success is based on research and development at the company-headquarters in Leobendorf, Austria. Croma´s Management Board has a clear vision for high-quality technologies and courageously seizes opportunities for in-licensing of or acquisitions of complementing companies. Croma-Pharma currently employs about 310 people and operates 11 subsidiaries. Through distribution partnerships, products are marketed in more than 70 countries. Croma-Pharma is an award winning company and celebrated its 40th anniversary in 2016.
For more information about Croma-Pharma, please visit: http://www.croma.at
Photocredits: Croma/Feelimage Matern
Photo1: Dr. Charalampos Arampatzis, Mag. Andreas Prinz, signing
SOURCE Croma-Pharma GmbH